


Claims


1. A platelet increasing agent comprising a 2-acylaminothiazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.



[Symbols in the formula have the following meanings.

A: a lower alkylene

- 10 R^1 : a group represented by the formula (II), or cyclic amino which may be substituted.



[Symbols in the formula have the following meanings.

- 15 R^{11} : H, a lower alkyl which may be substituted, or a cycloalkyl which may be substituted. When A represents methylene, R^{11} may be present as methylene which is bridged to thienyl or phenyl represented by R^2 . When A represents methylene, R^{11} may be present as a lower alkylene which may be substituted and which forms a ring closed at the methylene represented by A.
- 20

R¹²: a lower alkyl, a cycloalkyl or a non-aromatic heterocycle, each of which may be substituted.]

R²: thienyl or phenyl, each of which may be substituted.

5 R³: an aromatic heterocycle, an aryl or cyclic amino, each of which may be substituted.]

2. The pharmaceutical composition according to claim 1, wherein A is methylene.

10


3. The pharmaceutical composition according to claim 2, wherein R² is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting of a lower alkyl which may be substituted with
15 one or more halogens, and a halogen.

4. The pharmaceutical composition according to any of claims 1 to 3, which is a thrombocytopenia treating agent.

20

5. The pharmaceutical composition according to any of claims 1 to 3, which is a c-Mpl ligand.

6. A 2-acylaminothiazole derivative represented by
25 the formula (III) or a pharmaceutically acceptable salt thereof.



[Symbols in the formula have the following meanings.

B: a group represented by A according to claim 1.

R^4 : a group represented by R^1 according to claim 1.

5 R^5 : a group represented by R^2 according to claim 1.

R^6 : a group represented by R^3 according to claim 1,

provided that unsubstituted phenyl and indole
which may be substituted are excluded.]

10 7. The compound according to claim 6, wherein B is
 methylene.

8. The compound according to claim 7, wherein R⁵ is thienyl or phenyl, each of which is substituted with one or more groups selected from the group consisting of a lower alkyl which may be substituted with one or more halogens, and a halogen.

9. The compound according to claim 8, wherein R⁶ is
20 pyridyl which may be substituted, or phenyl which is
substituted.

10. The compound according to claim 9, wherein R⁶ is pyridin-3-yl whose 5-position is substituted with a group

selected from the group consisting of chloro and fluoro, and whose 6-position is substituted, or phenyl whose 3-position is substituted with a group selected from the group consisting of chloro and fluoro, whose 5-position is substituted with a group selected from the member consisting of -H, chloro and fluoro, and whose 4-position is substituted.

11. Among the compounds according to claim 6,

10 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl}piperidine-4-carboxylic acid,

15 1-(5-{[5-{(butyl(methyl)amino)methyl}-4-(4-chlorothiophen-2-yl)thiazol-2-yl]carbamoyl}-3-chloro-2-pyridyl)piperidine-4-carboxylic acid,

1-{5-[(4-(4-chlorothiophen-2-yl)-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-3-fluoro-2-pyridyl}piperidin-4-carboxylic acid,

20 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[(2S)-2-methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl}piperidine-4-carboxylic acid,

1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(dimethylaminomethyl)thiazol-2-yl]carbamoyl}-2-pyridyl)piperidine-4-carboxylic acid,

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-
{[isopropyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl}piperidine-4-carboxylic acid,

4-[[3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-
5 { [isopropyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl](methyl)amino]butyric acid,

1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[(3S)-3-
methylpyrrolidin-1-yl]methyl}thiazol-2-yl)carbamoyl]-2-
pyridyl}piperidine-4-carboxylic acid,

10 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[(2S)-2-
methoxypropyl](methyl)amino]methyl}thiazol-2-yl)carbamoyl]-
2-pyridyl}piperidine-4-carboxylic acid,

N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
2-yl)thiazol-2-yl]-5-chloro-6-[(3-
15 hydroxypropyl)amino]nicotinamide,

N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
2-yl)thiazol-2-yl]-5-chloro-6-(3-oxopiperazin-1-
yl)nicotinamide or

N-[5-{[butyl(methyl)amino]methyl}-4-(4-chlorothiophen-
20 2-yl)thiazol-2-yl]-5-chloro-6-[4-
(hydroxymethyl)piperidino]nicotinamide, or

a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the
25 compound according to any of claims 6 to 11 as an active
ingredient.

13. The pharmaceutical composition according to claim 12, which is a platelet increasing agent.

5 14. The pharmaceutical composition according to claim 12, which is a thrombocytopenia treating agent.

15. The pharmaceutical composition according to claim 12, which is a c-Mpl ligand.